Results (
Vietnamese) 1:
[Copy]Copied!
New approaches to the pharmacological treatment of dementia, and in particular to AD, began with the introduction of theacetylcholinesterase inhibitors, which inhibit the breakdown of acetylcholine, a neurotransmitter thought to be important in the chemical basis of a number of cognitive processes including memory, thought and judgement. Acetylcholine was also thought to be involved in some behavioural disturbances, although this is speculative. Acetylcholinesterase inhibitors used in clinical practice include rivastigmine, donepezil and galantamine.More recently, memantine has been introduced for the treatment of moderate to severe AD, again primarily used for its effect upon cognition, although some behavioural effects have been noted. Memantine works primarily through its action upon glutamatetransmission and more specifically on particular subtypes of receptors within glutamate systems particularly related to memory (N-methyl-D-aspartate [NMDA] receptors).
Being translated, please wait..